摘要
目的:探讨阿司匹林(ASA)、低分子肝素钙及其联合方案对子痫前期(PE)患者凝血功能指标及母婴结局的影响。方法:回顾性分析本院2018年8月-2020年5月收治的92例PE患者的临床资料,根据治疗方法不同分为ASA组(32例)、低分子肝素钙组(31例)及联合用药组(29例),ASA组予以ASA及对症治疗,低分子肝素钙组予以低分子肝素钙及对症治疗,联合用药组采用ASA联合低分子肝素钙及对症治疗。比较三组治疗前后凝血功能指标及母婴结局情况。结果:与治疗前相比,三组凝血功能治疗7 d后均明显改善(P<0.05);治疗7 d后,联合用药组凝血功能均优于ASA组与低分子肝素钙组(P<0.05),ASA组与低分子肝素钙组凝血功能比较差异无统计学意义(P>0.05)。联合组不良母婴结局发生率为6.25%,显著低于ASA组的32.26%和低分子肝素钙组的34.48%,差异有统计学意义(P<0.05)。三组不良反应总发生率比较差异无统计学意义(P>0.05)。结论:ASA联合低分子肝素钙可减轻PE患者的凝血功能亢进状态,有效改善母婴结局,值得临床推广。
Objective:To investigate the influence of Aspirin(ASA),Low Molecular Weight Heparin Calcium and their combined regimens on coagulation function and maternal and infant outcomes in patients with preeclampsia(PE).Method:The clinical data of 92 PE patients treated in our hospital from August 2018 to May 2020 were retrospectively analyzed.According to different treatment methods,they were divided into the ASA group(32 cases),the low molecular weight heparin calcium group(31 cases)and the combined drug group(29 cases).The ASA group was treated with ASA and symptomatic treatment,the Low Molecular Weight Heparin Calcium group was treated with Low Molecular Weight Heparin Calcium and symptomatic treatment,and the combined drug group was treated with ASA combined with Low Molecular Weight Heparin Calcium and symptomatic treatment.The coagulation function indexes and maternal and infant outcomes of the three groups before and after treatment were compared.Result:Compared with the pre-treatment,the coagulation functions of the three groups were significantly improved after 7 d of treatment(P<0.05);after 7 d of treatment,the coagulation function of the combined drug group was better than that of the ASA group and the Low Molecular Weight Heparin Calcium group(P<0.05),there was no significant difference in coagulation function between the ASA group and the Low Molecular Weight Heparin Calcium group(P>0.05).The incidence of adverse maternal and child outcomes in the combined group was 6.25%,which was significantly lower than 32.26%in the ASA group and 34.48%in the Low Molecular Weight Heparin Calcium group,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions among the three groups(P>0.05).Conclusion:ASA combined with Low Molecular Weight Heparin Calcium can alleviate hypercoagulability in PE patients and effectively improve maternal and infant outcomes,which is worthy of clinical promotion.
作者
缪丽琳
姜艳艳
郑文芳
MIAO Lilin;JIANG Yanyan;ZHENG Wenfang(Houjie Hospital in Dongguan,Dongguan 523960,China)
出处
《中外医学研究》
2021年第8期67-70,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
基金
东莞市社会科技发展(一般)项目(2019507145023726)。
关键词
阿司匹林
低分子肝素钙
子痫前期
母婴结局
凝血功能
Aspirin
Low Molecular Weight Heparin Calcium
Preeclampsia
Maternal and infant outcomes
Coagulation function
